Abstract: Bullous systemic lupus erythematosus (BSLE) is a unique variant of SLE, characterized by its pathogenesis being notably linked to autoantibodies that target type Ⅶ collagen. The disease predominantly impacts young women aged between 20 and 40 years. This paper reports a young male diagnosed patient with BSLE who exhibited a suboptimal response to treatments such as glucocorticoids, Janus kinase (JAK) inhibitors, immunomodulators, and immunoglobulin therapy. However, the patient experienced a significant improvement following administration of dapsone.

Key words: bullous systemic lupus erythematosus, bullae, dapsone